在感染HIV-1的儿童中，含茚地那韦/低剂量利托那韦的高效抗逆转录病毒疗法具有强大的抗逆转录病毒活性，但会引发副作用且治疗常被中断。
Indinavir/low-dose ritonavir containing HAART in HIV-1 infected children has potent antiretroviral activity, but is associated with side effects and frequent discontinuation of treatment.
作者信息
Fraaij P L A, Verweel G, van Rossum A M C, Hartwig N G, Burger D M, de Groot R
机构信息
Dept. of Pediatrics, Erasmus MC-Sophia Children's Hospital, Dr. Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands.
出版信息
Infection. 2007 Jun;35(3):186-9. doi: 10.1007/s15010-007-6068-1.
Abstract
We here present the study results of 21 HIV-1 infected children who were treated with indinavir plus low-dose ritonavir and two nucleoside reverse transcriptase inhibitors (NRTIs) for 48 weeks. Although this q12h HAART regimen had potent antiretroviral activity, it was frequently associated with side effects and discontinuation of therapy.
摘要
我们在此呈现21名感染HIV-1的儿童的研究结果，这些儿童接受茚地那韦加低剂量利托那韦以及两种核苷类逆转录酶抑制剂（NRTIs）治疗48周。尽管这种每12小时一次的高效抗逆转录病毒疗法（HAART）方案具有强大的抗逆转录病毒活性，但它常常伴有副作用并导致治疗中断。
相似文献
1
Indinavir/low-dose ritonavir containing HAART in HIV-1 infected children has potent antiretroviral activity, but is associated with side effects and frequent discontinuation of treatment.在感染HIV-1的儿童中，含茚地那韦/低剂量利托那韦的高效抗逆转录病毒疗法具有强大的抗逆转录病毒活性，但会引发副作用且治疗常被中断。
Infection. 2007 Jun;35(3):186-9. doi: 10.1007/s15010-007-6068-1.
2
3
Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects.洛匹那韦/利托那韦与茚地那韦/利托那韦用于初治HIV感染患者的抗逆转录病毒治疗：免疫病毒学结果及副作用
Antiviral Res. 2004 Apr;62(1):53-6. doi: 10.1016/j.antiviral.2003.12.002.
4
Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily.基于茚地那韦/利托那韦的疗法用于初治的HIV-1感染患者：每日两次800/100毫克与400/100毫克的比较
HIV Med. 2005 Jan;6(1):1-6. doi: 10.1111/j.1468-1293.2005.00255.x.
5
Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.接受抗逆转录病毒药物治疗的HIV疾病患者的脂质代谢紊乱：发生率、与所用药物的关系以及苯扎贝特降脂治疗的作用
J Infect. 2001 Apr;42(3):181-8. doi: 10.1053/jinf.2001.0829.
6
Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.利托那韦增强型双蛋白酶抑制剂疗法在初治HIV-1感染患者中的疗效和安全性：2IP ANRS 127研究
J Antimicrob Chemother. 2009 Jul;64(1):118-25. doi: 10.1093/jac/dkp146. Epub 2009 May 6.
7
Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.洛匹那韦/利托那韦用于接受过治疗的垂直感染HIV儿童的高效抗逆转录病毒疗法的长期疗效
J Antimicrob Chemother. 2008 Jan;61(1):183-90. doi: 10.1093/jac/dkm436. Epub 2007 Nov 19.
8
Switch from ritonavir to indinavir in combination therapy for HIV-1-infected children.
Clin Infect Dis. 2005 Apr 15;40(8):1181-7. doi: 10.1086/428833. Epub 2005 Mar 2.
9
Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.在人类免疫缺陷病毒患者中换用基于阿扎那韦-利托那韦的高效抗逆转录病毒疗法后的降脂疗效及安全性
Pharmacotherapy. 2008 Mar;28(3):323-30. doi: 10.1592/phco.28.3.323.
10
The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.接受抗逆转录病毒治疗3年后病毒载量无法检测的患者每日一次服用沙奎那韦/利托那韦的48周疗效。
HIV Med. 2005 Mar;6(2):122-8. doi: 10.1111/j.1468-1293.2005.00274.x.
本文引用的文献
1
Pharmacokinetics of antiretroviral therapy in HIV-1-infected children.抗逆转录病毒疗法在HIV-1感染儿童中的药代动力学
Clin Pharmacokinet. 2005;44(9):935-56. doi: 10.2165/00003088-200544090-00004.
2
Pharmacokinetics of indinavir combined with low-dose ritonavir in human immunodeficiency virus type 1-infected children.茚地那韦联合小剂量利托那韦在1型人类免疫缺陷病毒感染儿童中的药代动力学
Antimicrob Agents Chemother. 2004 May;48(5):1904-7. doi: 10.1128/AAC.48.5.1904-1907.2004.
3
Treatment of antiretroviral-drug-resistant HIV-1 infection.抗逆转录病毒药物耐药性HIV-1感染的治疗。
Lancet. 2003 Dec 13;362(9400):2002-11. doi: 10.1016/S0140-6736(03)15022-2.
4
Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children.新型蛋白酶抑制剂洛匹那韦/利托那韦用于人类免疫缺陷病毒感染儿童的48周评估。
Pediatr Infect Dis J. 2003 Mar;22(3):216-24. doi: 10.1097/01.inf.0000055061.97567.34.
5
Results of 2 years of treatment with protease-inhibitor--containing antiretroviral therapy in dutch children infected with human immunodeficiency virus type 1.荷兰感染1型人类免疫缺陷病毒儿童接受含蛋白酶抑制剂抗逆转录病毒治疗2年的结果
Clin Infect Dis. 2002 Apr 1;34(7):1008-16. doi: 10.1086/339443. Epub 2002 Mar 4.
6
Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children.蛋白酶抑制剂茚地那韦在1型人类免疫缺陷病毒感染儿童中的药代动力学。
Antimicrob Agents Chemother. 2001 Mar;45(3):701-5. doi: 10.1128/AAC.45.3.701-705.2001.
7
Pharmacokinetics of indinavir and low-dose ritonavir in children with HIV-1 infection.
AIDS. 2000 Sep 29;14(14):2209-10. doi: 10.1097/00002030-200009290-00022.
8
3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine.茚地那韦、齐多夫定和拉米夫定对HIV病毒血症的3年抑制作用。
Ann Intern Med. 2000 Jul 4;133(1):35-9. doi: 10.7326/0003-4819-133-1-200007040-00007.
9
Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers.健康志愿者中利托那韦与茚地那韦的药代动力学相互作用。
Antimicrob Agents Chemother. 1998 Nov;42(11):2784-91. doi: 10.1128/AAC.42.11.2784.
10
Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations.儿童期血液淋巴细胞的免疫表型分析。淋巴细胞亚群的参考值。
J Pediatr. 1997 Mar;130(3):388-93. doi: 10.1016/s0022-3476(97)70200-2.
Zotero 插件